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Objective. To quantify diﬀerences in results obtained by immunoassays (IAs) and tandem mass spectrometry (MSMS) for cortisol
and free thyroxine (FT4). Design & Patients. Cortisol was measured over 60 minutes following a standard ACTH stimulation test
(n = 80); FT4 was measured over time in two cohorts of pregnant (n = 57), and nonpregnant (n = 28) women. Measurements.
Samples were analyzed with both IA and MSMS. Results. Results for cortisol by the two methods tended to agree, but agreement
weakened over the 60-minute test and was worse for higher (more extreme) concentrations. The results for FT4 depended on
the method. IA measurements tended to agree with MSMS measurements when values fell within “normal levels”, but agreement
was not constant across trimester in pregnant women and was poorest for the extreme (low/high) concentrations. Correlations
between MSMS measurements and the diﬀerence between MSMS and IA results were strong and positive (0.411 <r< 0.823;
all P<. 05). Conclusions. IA and MSMS provide diﬀerent measures of cortisol and FT4 at extreme levels, where clinical decision
making requires the greatest precision. Agreement between the methods is inconsistent over time, is nonlinear, and varies with the
analyte and concentrations. IA-based measurements may lead to erroneous clinical decisions.
1.Introduction
Inthispaper,wecomparetheagreement[1–7]ofimmunoas-
say (IA) and tandem mass spectrometry (MSMS) in the
measurement of the concentrations of two analytes, cortisol,
and free T4. Both analytes are critical for normal growth and
development, and survival. Thyroid hormone regulates the
expression of multiple genes and is necessary to maintain
normal function in virtually all organ systems of the body
[8].
Cortisol regulates normal responses to stress, and is
important for vascular reactivity, carbohydrate metabolism,
and immune function [9]. Cortisol measurement is the basis
for diagnosing adrenal insuﬃciency or conditions of gluco-
corticoid excess. Mismeasurement of cortisol could lead to
withholdingtreatmentforpatientswithadrenalinsuﬃciency
or Cushings syndrome, which could have life-threatening
consequences. Similarly, incorrect diagnosis of these con-
ditions exposes patients to the toxic side eﬀects of steroid
or steroid-lowering therapies, without any expected beneﬁt.
FT4 is one of the analytes used to titrate the treatment
of hypothyroidism and hyperthyroidism. Erroneous analyte
values could lead to mismanagment of these disorders. This
is a particular concern in vulnerable populations such as the
young, the elderly, those who are pregnant, those suﬀering
from cardiac disease, or those who have thyroid cancer.
Although FT4 is interpreted in conjunction with a thyroid
stimulating hormone (TSH) level, there are circumstances
under which TSH measurements are unreliable [10]. It has
also been suggested that during pregnancy a decreased FT42 International Journal of Analytical Chemistry
Table 1: Descriptive statistics for cortisol (Table 1(a)) and Free
T4(Table 1(b)).
(a) Cortisol (mcg/dl) over a 60 minute test period by MS-MS and IA (N =
80). Note that agreement is not universal on reference ranges. However,
Reference range for random cortisol by IA in most clinical laboratories = 4
–22mcg/dl ([23]; see also [24]).
MSMS: MEAN (SD) IA: MEAN (SD)
cortisol T = 0 9.498 (6.08) 8.508 (4.99)
cortisol T = 30 21.982 (10.24) 20.553 (8.96)
cortisol T = 60 25.758 (12.22) 23.844 (10.74)
(b) Free T4 (FT4, ng/dl) over 3 trimesters of pregnancy, and in
nonpregnant women. Note that agreement on reference ranges for FT4 in
pregnant women is not universal. Kahric-Janicic et al. (2007) [25]s u g g e s t
ranges between 0.6 and 1.4ng/dL for FT4 in pregnant women; results
vary by trimester for both MSMS and IA. Reference intervals for FT4 in
nonpregnantwomenbytandemmassspectrometryare0.8–2.1ng/dL[24].
Ranges for this analyte in nonpregnant women by IA are lower and have a
smaller range, typically around 0.7–1.5ng/dL [26].
MSMS: MEAN
(SD), N IA: MEAN (SD), N
FT4, trimester 1 1.125 (.23), 59 1.071 (.22), 61
FT4, trimester 2 0.915 (.31), 36 0.795 (.17), 42
FT4, trimester 3 0.863 (.22), 26 0.875 (.18), 35
FT4, nonpregnant
women 0.928 (.26), 28 1.102 (.25), 28
concentration,notanelevatedTSH,speciﬁcallyplacesafetus
at risk [11–13]. Thus accurate determination of FT4 will best
serve the clinician who wishes to make an informed clinical
decision.
Direct/analogue immunoassay (IA) methods for the
measurement of FT4 are widely used and are controversial
[14–17], and there is discrepancy between diﬀerent IAs
[18–20]. Recent reports of problems with IAs for the
measurement of steroids in general have identiﬁed lack
of speciﬁcity as the key cause of unreliability [21, 22].
In this paper, we compare measurements of cortisol and
FT4 concentrations made by IA and MSMS plotting the
mean versus the diﬀerence between two measures of a
single analyte. It is important to note here that we seek
to quantify the agreement between the two measurement
methods and/or their disagreement, and not quantify or
correct for the degree of disagreement.
2. Methods
2.1. Overview. This study represents secondary analyses of
previously existing data [24, 25]. There were two diﬀerent
c o h o r t sf o rw h o ma n a l y t em e a s u r e m e n t sw e r ea l r e a d ya v a i l -
able. Brieﬂy, the cohort for whom cortisol measurements
were available consisted of 80 subjects [24] who underwent
an outpatient cortrosyn stimulation test as part of an
evaluation for adrenal insuﬃciency [27, 28]. The reference
interval for cortisol is 3–21mg/dL (Soldin SJ, unpublished
data). FT4 measurements were available for 28 clinically
and biochemically euthyroid nonpregnant women and 98
clinically and biochemically euthyroid pregnant women
who underwent testing during one or more trimesters of
pregnancy [25]. The reference interval for FT4 is 0.9–
1.6ng/dL in nonpregnant women which is the same as the
pediatric reference range [29]. We compared assay results
from IA and MSMS using the means-diﬀerence plots. We
would conclude that the methods agree if we observe no
relationship between data points plotted on these axes [2–4].
2.2. Samples. Samples for cortisol and FT4 were collected in
plastic red top tubes (containing clot activator, Vacutainer,
manufactured by Becton Dickenson, Franklin Lakes, NJ
07417) and allowed to clot for 20 minutes. The samples were
then centrifuged at 4,000rpm for 10min, serum separated
and immediately stored at minus 80
◦C until measurement
of the analytes by the General Clinical Research Center
Bioanalytical Core Laboratory. Cortisol concentrations are
reported in µg/dL at baseline and then 30 minutes and
60 minutes after cortrosyn injection. This diagnostic test,
which involves injection of synthetic adrenocorticotropic
stimulating hormone (cortrosyn), is a common test for
diagnosing adrenal insuﬃciency in clinical situations [28].
FT4 measurements were obtained either in the nonpregnant
state or during successive trimesters of pregnancy and are
reported in ng/dL.
2.3. Assays
2.3.1. Immunoassays. Cortisol was measured on the DPC
Immulite1000(DiagnosticProductsCorporation,LosAnge-
les, CA) while FT4s were measured on the Dade RxL
Dimension (Dade-Behring Diagnostics, Glasgow, DE).
2.3.2. LC/MS/MS. Both the cortisol and FT4s were assayed
as previously published in [17, 20–22]. Both assays were
performed using the API-5000 tandem mass spectrome-
ter (Applied Biosystems, Foster City, CA), and both use
deuterated internal standards. Cortisol measurement was
performed on 200µLs e r u m[ 22], while FT4 was measured
onaserumultraﬁltrate[17,20].Assayvalues(concentrations
of cortisol or FT4) were obtained via IA and MSMS at each
of the time points relevant for the two analytes.
2.3.3. Statistical Methods. Data in each study cohort were
analyzed separately using a Bland-Altman (BA) or means-
diﬀerence plot for the IA-MSMS pairs of measurements. The
“summary” of data in the BA plot is reﬂected in reference
lines at zero, representing the ideal mean diﬀerence between
the two measures, and the values one standard deviation
(solid lines) and two standard deviations (short dashed
lines) away from zero (long dashed line) on the Y axis,
with zero being the point on the Y axis where the two
methods agree perfectly and the lines within one standard
deviation bounding the acceptable range for variability in
agreement. Pearson correlation coeﬃcients were computed
to determine if there was a signiﬁcant association betweenInternational Journal of Analytical Chemistry 3
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Figure 1: Bland-Altman plot of Cortisol ((mcg/dl) at T = 0( a ) ,T = 30 (b), and T = 60 (c) minutes) in the cortisol response test: diﬀerence
MSMS-IA on Y axis and average on X axis. N = 80. Reference line at zero and pairs of lines at ±1SD and ±2SD.
the diﬀerence between measurements (MSMS-IA) and one
of the measurements (MSMS), which would reﬂect signiﬁ-
cant disagreement [7].
3. Results
The data are shown ﬁrst for cortisol values at baseline and
then 30 and 60 minutes after cortrosyn injection and then
for free T4 values sampled in the nonpregnant state and then
duringthesuccessivetrimestersofpregnancy.TablesI(a)and
I(b) present descriptive statistics for cortisol (1A) and FT4
(1B) across the relevant time points.
3.1. Cortisol. Figure 1 shows the Bland-Altman (BA) plot of
the IA and MSMS measurements for the cortisol measure-
ments initially (T0, Figure 1(a)), at 30- (T30, Figure 1(b))
and 60-minutes (T60, Figure 1(c)).
A clear trend in increasing variance is observed along
the X-axis (representing the mean of the two measures).
Lower concentrations of cortisol measured by IA or MSMS
were fairly closely associated, but as the values increase, the
divergence becomes larger. This heteroscedasticity within the
data at the 30 minute point of the cortisol response test
is larger, and reﬂects a larger range of cortisol values, than
were observed at baseline (Figure 1(a)). The same tendency
towards increasing variance is apparent in Figure 1(c) (60
minutes after the injection).
Table 2 presents the correlation coeﬃcients estimating
the strength of association between the diﬀerence between
the two measures of cortisol and the MSMS results for
cortisol. MSMS results are strongly and positively correlated
with the diﬀerence.
3.2. FT4. Figure 2 shows the Bland-Altman (BA) plots of the
IA and MSMS measurements for FT4 measured in the ﬁrst4 International Journal of Analytical Chemistry
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Figure 2: Bland-Altman plots of FT4 (ng/dl), ﬁrst trimester (T1, 2A), second trimester (T2, 2B), 3rd trimester (T3, 2C), and in nonpregnant
(NP, 2D) women. Diﬀerence (MSMS-IA) on Y axis and average value from IA and MSMS on X axis. (Pregnant cohort N with both ranges
from 59 (T1) to 26 (T3); nonpregnant cohort N is 28.) Reference line at zero and pairs of lines at ±1SD and ±2SD.
Table 2:PearsoncorrelationsofdiﬀerencebetweenmethodsversusMSMSalone,forCortisol(N = 80).MSMSand(MSMS-IA)correlations
reﬂect signiﬁcant diﬀerences in the variances of the measurements by IA versus MSMS over time.
DIFFERENCE Cortisol by MSMS,
T = 0
Cortisol by MSMS,
T = 30 min
Cortisol by MSMS,
T = 60 min
T = 0 min, MSMS-IA 0.650 ∗
T = 30 min, MSMS-IA 0.494 ∗
T = 60 min, MSMS-IA 0.480 ∗
All Pearson correlation coeﬃcients signiﬁcant at P ≤ .001. ∗ indicates signiﬁcant diﬀerences in the variances of the measurements by IA versus MSMS.
trimester (T1, 2A), second (T2, 2B) and third trimesters (T3,
2C) for a single group of pregnant women followed over
time, and a fourth group of women who were not pregnant
(NP, 2D).
Thepatternsinthemeans-diﬀerenceplotsarenotasclear
cut for FT4 as for cortisol. In the ﬁrst trimester (T1, Figure
2(a)), the variability in disagreement appears to increase as
the average increases (fan shape), while in T2 and T3 the
diﬀerence itself seems to increase as the average increases
(positive slope). For the nonpregnant women, a diﬀerent
pattern is observed, with the majority of points reﬂecting
greater FT4 values from IA relative to those from MSMS.
Table 3 presents the correlation matrix for the diﬀerence
in FT4 measured by MSMS and IA with MSMS.International Journal of Analytical Chemistry 5
Strong, positive correlations were observed between
the diﬀerence between the two methods and MSMS mea-
surements of FT4 over the three trimesters and in the
nonpregnant state, suggesting that the patterns reﬂected
in Figures 2(a)–2(d) represent signiﬁcant diﬀerences in
the variances of the measurements of FT4 by IA versus
MSMS.
4. Discussion and Conclusions
This study of two methods to assay FT4 and cortisol
over time showed nonlinear disagreement between analytes
measured by immunoassay and tandem mass spectrometry.
The diﬀerences were more dramatic for cortisol than for FT4
but signiﬁcant correlation coeﬃcients reﬂected “genuine”
trends of increasing variance associating with increased
analyte concentration, and over time, for both analytes.
In these correlations, we treated MSMS as the standard
measurement; IA results are derived through a mathematical
formula in the direct/analogue methods used in the great
majority (>99%) of clinical laboratories.
Ourresultssuggestsigniﬁcantvariation(heteroscedastic-
ity) and nonequivalence of these two methods. This could
simply reﬂect poor reliability in IA for these analytes but in
the case of FT4 it is also perhaps suggestive that the variation
in disagreement over trimesters could also have varying
causes (i.e., that vary with pregnancy, e.g., heterophilic
antibodies, changes in protein binding, etc.). Although the
agreement was worse for cortisol, correlations between the
diﬀerence in results from the two methods and MSMS was
signiﬁcant for both analytes and at each of the time points.
The purpose of this work is not to provide cor-
rect/correctedvaluesfortheanalytesinthesepopulationsbut
rathertohighlightareaswhereinterpretation/interpretability
might be compromised by unreliability and/or failures of
modeling assumptions (such as heteroscedasticity and time-
sensitive variability). As noted earlier, this study sought
to quantify the agreement between the two measurement
methods and/or their disagreement, and not to quantify or
correct for the degree of disagreement. The magnitudes of
the diﬀerences our analyses discovered could be clinically
relevant. For example, in the evaluation of adrenal insuﬃ-
ciency they could make the diﬀerence between concluding
someone has adrenal insuﬃciency or adrenal suﬃciency. In
thisparticularcohortof patients, 11.5% of thosetested could
be given a diﬀerent diagnosis (adrenal insuﬃciency versus
adrenal suﬃciency) depending on which assay was used to
make the diagnosis. Similarly, the diﬀerences between the
thyroid hormone assays are clinically relevant, particularly in
thepregnantpopulationwherethethyroidhormoneconcen-
tration could be most relevant for fetal health [11–13]. Here,
our samples did not permit distinction of diagnosis on the
basis of IA or MSMS, but this has been found in a current
example of FT4 results where 5/46 (10.9%) of patients had
IA results for FT4 that could have led to misdiagnosis [20].
Our results suggest that immunoassay and tandem mass
spectrometry cannot be considered to yield interchangeable
results. The methods did not agree and this disagreement
became more extreme and less predictable at higher concen-
trations of the analytes we studied. As the true concentration
becomes more extreme, so does the discrepancy between IA
and MSMS results. The implication of this for clinicians is
that patients with analyte values at the extremes are more
likely to be misdiagnosed/mismeasured when IA is used (see
[17, 20, 24, 25].
Since the extreme observations are by deﬁnition rare
outcomes, they might appear to be outliers and not con-
tribute much (particularly in larger samples) to decrease the
R2. This can artiﬁcially inﬂate conﬁdence in overall ﬁt of
a transformation to the data and can lead to undetected
incorrectclinicaldecisionsifIAisusedandhomoscedasticity
is assumed.
Our results demonstrate good agreement between IA
and MSMS in the concentration range of least interest—
that is, at normal levels [20, 23–26, 29]. More importantly,
the methods do not give similar results over time and over
the actual concentration of cortisol and, to a lesser but
still “genuine” extent, FT4. MSMS has been compared to
equilibrium dialysis [25] for analytes including FT4 with
excellent agreement.
IA and MSMS methods have been compared elsewhere
[17–20], suggesting that IA methods lack speciﬁcity and are
also subject to interferences from altered binding proteins
and nonspeciﬁc heterophilic antibodies—which are preva-
lent during pregnancy (possibly contributing to some of
our results). Direct analogue FT4 IA methods have been
found to give false results at both the low and high ends of
the value continuum [17–20]. Diﬀerent serum matrices can
aﬀe c tI A sb u ta r ef a rl e s sl i k e l yt oa ﬀect MSMS methods.
The latter do not cross-react with similar compounds or
metabolites, and so are more speciﬁc. Immunoassays, in
contrast, may cross-react with similar compounds as well as
with many metabolites. The precision or reproducibility of
MSMS methods and IA methods are similar, although some
IA methods could repeatedly provide a precise, and incorrect
value. Drawbacks to MSMS methods are that they require
more highly trained operators and generally are slower, with
a lower throughput than IAs. Several university, hospital and
commercial laboratories are moving from the non-speciﬁc
immunoassay platforms to the more speciﬁc tandem mass
spectrometry procedures for steroid and thyroid hormone
measurement. This trend is accelerating and the number
of laboratories using tandem MSMS and participating in
the College of American Pathologists Proﬁciency Testing
Program is increasing signiﬁcantly each year.
In conclusion, these analyses demonstrate statistically
signiﬁcant disagreement in the measurement of two analytes
at levels outside of the reference range by two diﬀerent
assays. It is important for physicians who are making clinical
decisions to be aware that the analyte value they are provided
with varies depending on the assay used to generate the
data. Clinicians may be surprised to discover that the clinical
decision they reach may be impacted by the assay employed.
The mechanism of action of the MSMS assay relative to
that of IA methods support MSMS as the more speciﬁc and
accurate assay (see also [14, 16–20]). Since disagreement
is most pronounced at the extremes (highest/lowest) and6 International Journal of Analytical Chemistry
Table 3: Pearson correlations of diﬀerence between methods versus MSMS alone, for Free T4 (FT4). MSMS and (MSMS-IA) correlations
reﬂect signiﬁcant diﬀerences in the variances of the measurements by IA versus MSMS over time, and for nonpregnant women (NP)
measured at one time only. (Pregnant cohort N with both ranges from 59 (T1) to 26 (T3); Nonpregnant cohort N is 28.)
DIFFERENCE FT4 by MSMS, over time (and for NP)
FT4 by MSMS, T1 FT4 by MSMS, T2 FT4 by MSMS, T3 FT4 by MSMS, NP
FT4, T1 MSMS-IA 0.598†
∗ —
FT4, T2 MSMS-IA 0.823†
∗ —
FT4, T3 MSMS-IA 0.723†
∗ —
FT4, NP MSMS-IA ———0 . 4 1 1 †
∗
† Pearson correlation coeﬃcient signiﬁcant at P<. 05.∗indicates signiﬁcant diﬀerences in the variances of the measurements by IA versus MSMS.
clinical intervention is typically based on values in these
ranges, we feel that MSMS is the more robust method for
assay.
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